KIA
CAI

Knollwood Investment Advisory’s Caris Life Sciences CAI Stock Holding History

Knollwood Investment Advisory’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$187K Hold
10,445
– – 0.02% 301
2025
Q4 		$282K Buy
+10,445
New +$294K 0.03% 289

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Knollwood Investment Advisory's CAI Position: Q1 2026 in Review

Knollwood Investment Advisory held its Caris Life Sciences (CAI) position steady in Q1 2026 at 10,445 shares worth $187K. The position accounts for 0.02% of the portfolio, ranked #301.

Knollwood Investment Advisory first reported a position in CAI in Q4 2025 and has held it in 2 quarters since. The position peaked at $282K in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Knollwood Investment Advisory held 10,445 shares of Caris Life Sciences worth $187K as of Q1 2026.
  • Knollwood Investment Advisory left its Caris Life Sciences share count unchanged in Q1 2026.
  • Caris Life Sciences made up 0.02% of Knollwood Investment Advisory's portfolio in Q1 2026, its #301 holding.
  • Knollwood Investment Advisory first reported a position in Caris Life Sciences in Q4 2025 and has held it in 2 quarters since.
  • Knollwood Investment Advisory's Caris Life Sciences position peaked at $282K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Knollwood Investment Advisory's 13F filing for Q1 2026, filed 14 May 2026.